Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization

Colin S Tan,1,2 SriniVas R Sadda3 1National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore; 2Fundus Image Reading Center, National Healthcare Group Eye Institute, Singapore; 3Doheny Eye Institute, University of California Los Angeles, CA, USA Abstract: Myopic choroidal neovascul...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tan CS, Sadda SR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Myopic choroidal neovascularization ranibizumab anti-vascular endothelial growth factor Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/93f14c634ca5426ba9dd5b7e646b0f42
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:93f14c634ca5426ba9dd5b7e646b0f42
record_format	dspace
spelling	oai:doaj.org-article:93f14c634ca5426ba9dd5b7e646b0f422021-12-02T06:46:31ZAnti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization1177-5483https://doaj.org/article/93f14c634ca5426ba9dd5b7e646b0f422017-09-01T00:00:00Zhttps://www.dovepress.com/anti-vascular-endothelial-growth-factor-therapy-for-the-treatment-of-m-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Colin S Tan,1,2 SriniVas R Sadda3 1National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore; 2Fundus Image Reading Center, National Healthcare Group Eye Institute, Singapore; 3Doheny Eye Institute, University of California Los Angeles, CA, USA Abstract: Myopic choroidal neovascularization (CNV) is a sight-threatening condition which occurs in eyes with myopia, particularly in those with pathologic myopia. It is the most common cause of CNV among patients younger than 50 years. Hemorrhage and exudation from the CNV lesion may eventually result in scarring or chorioretinal atrophy. While myopic CNV was previously treated with focal laser photocoagulation or photodynamic therapy (PDT), the current treatment of choice is anti-vascular endothelial growth factor (VEGF) agents. Many studies have demonstrated the efficacy of intravitreal anti-VEGF agents in the treatment of myopic CNV. The RADIANCE study reported that intravitreal ranibizumab was superior to PDT in eyes with myopic CNV (at 3 months, both groups receiving intravitreal ranibizumab gained 10.5 and 10.6 letters vs 2.2 letters among patients receiving PDT). In addition, the study demonstrated similar visual outcomes in eyes treated on the basis of visual acuity stabilization or disease activity criteria. Other clinical studies have provided evidence for the efficacy of ranibizumab and aflibercept in the treatment of myopic CNV. This review addresses the epidemiology, pathophysiology, and imaging characteristics of myopic CNV, and discusses the evidence for the efficacy of anti-VEGF agents as compared to laser photocoagulation and PDT. Keywords: myopic choroidal neovascularization, ranibizumab, anti-vascular endothelial growth factorTan CSSadda SRDove Medical PressarticleMyopic choroidal neovascularizationranibizumabanti-vascular endothelial growth factorOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 1741-1746 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Myopic choroidal neovascularization ranibizumab anti-vascular endothelial growth factor Ophthalmology RE1-994
spellingShingle	Myopic choroidal neovascularization ranibizumab anti-vascular endothelial growth factor Ophthalmology RE1-994 Tan CS Sadda SR Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization
description	Colin S Tan,1,2 SriniVas R Sadda3 1National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore; 2Fundus Image Reading Center, National Healthcare Group Eye Institute, Singapore; 3Doheny Eye Institute, University of California Los Angeles, CA, USA Abstract: Myopic choroidal neovascularization (CNV) is a sight-threatening condition which occurs in eyes with myopia, particularly in those with pathologic myopia. It is the most common cause of CNV among patients younger than 50 years. Hemorrhage and exudation from the CNV lesion may eventually result in scarring or chorioretinal atrophy. While myopic CNV was previously treated with focal laser photocoagulation or photodynamic therapy (PDT), the current treatment of choice is anti-vascular endothelial growth factor (VEGF) agents. Many studies have demonstrated the efficacy of intravitreal anti-VEGF agents in the treatment of myopic CNV. The RADIANCE study reported that intravitreal ranibizumab was superior to PDT in eyes with myopic CNV (at 3 months, both groups receiving intravitreal ranibizumab gained 10.5 and 10.6 letters vs 2.2 letters among patients receiving PDT). In addition, the study demonstrated similar visual outcomes in eyes treated on the basis of visual acuity stabilization or disease activity criteria. Other clinical studies have provided evidence for the efficacy of ranibizumab and aflibercept in the treatment of myopic CNV. This review addresses the epidemiology, pathophysiology, and imaging characteristics of myopic CNV, and discusses the evidence for the efficacy of anti-VEGF agents as compared to laser photocoagulation and PDT. Keywords: myopic choroidal neovascularization, ranibizumab, anti-vascular endothelial growth factor
format	article
author	Tan CS Sadda SR
author_facet	Tan CS Sadda SR
author_sort	Tan CS
title	Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization
title_short	Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization
title_full	Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization
title_fullStr	Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization
title_full_unstemmed	Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization
title_sort	anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/93f14c634ca5426ba9dd5b7e646b0f42
work_keys_str_mv	AT tancs antivascularendothelialgrowthfactortherapyforthetreatmentofmyopicchoroidalneovascularization AT saddasr antivascularendothelialgrowthfactortherapyforthetreatmentofmyopicchoroidalneovascularization
_version_	1718399765542076416

Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization

Ejemplares similares